Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 42

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 42
---
 information about such accounts and withhold 30% on payments
to non-compliant foreign financial institutions and certain other account holders.

Any cash paid to a non-U.S. holder as
a result of the Reverse Stock Split that is treated as dividend may be subject to withholding under FATCA unless the requirements set
forth above are satisfied (if applicable) and appropriate certifications are made. While withholding under FATCA would have applied also
to payments of gross proceeds from the sale or other disposition of our Common Stock on or after January 1, 2019, proposed Treasury regulations
eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury regulations
until final Treasury regulations are issued.

Interests of Directors and Executive Officers

Our directors and executive officers have no substantial
interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our
Common Stock.

Vote Required

The affirmative vote of a majority of the votes cast
by the holders of all shares of stock present or represented and voting on the Reverse Stock Split Proposal at the Annual Meeting is required
to approve the Reverse Stock Split Proposal. This means that to be approved, the votes cast in favor of the Reverse Stock Split Proposal
must exceed the votes cast against the Reverse Stock Split Proposal. Since abstentions are not considered votes cast, they will have no
effect on this proposal. Broker non-votes are not expected for this proposal because we believe this matter is a routine matter. If there
were to be any broker non-votes they would have no effect on the vote with respect to this proposal.

Approval by our stockholders of the Reverse Stock Split Proposal is not conditioned upon approval by our stockholders of the Authorized Increase Proposal (Proposal No. 5); conversely, approval by our stockholders of the Authorized Increase Proposal is not conditioned upon approval by our stockholders of the Reverse Stock Split Proposal.

<div align='center'>THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” APPROVAL OF
THE REVERSE STOCK SPLIT PROPOSAL.</div>

| 23 |

<div align='center'>PROPOSAL NO. 4

APPROVAL OF THE WARRANT EXERCISE</div>

We are seeking stockholder approval for the issuance
of up to 2,926,166 shares of our Common Stock upon the exercise of common stock purchase warrants that were issued in connection with
our private placement offering (the “Private